Merck Takes Legal Action Against U.S. Government's Drug Price Negotiation Powers
TL;DR Summary
Merck is challenging the US government's new powers to negotiate drug prices, arguing that the government's approach is unconstitutional and exceeds its authority. The legal challenge comes as the Biden administration seeks to lower drug prices and increase access to affordable healthcare.
- Merck Challenges U.S. Government's New Powers to Negotiate Drug Prices The Wall Street Journal
- Merck Sues Over Medicare Drug-Price Negotiation Law The New York Times
- Merck sues Biden administration over Medicare drug price negotiations CNBC
- Merck sues US government to halt Medicare drug price negotiation Reuters
- N.J. drugmaker sues federal government, calling price negotiation plan ‘extortion’ NJ.com
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
0 min
vs 1 min read
Condensed
5%
44 → 42 words
Want the full story? Read the original article
Read on The Wall Street Journal